Open AccessTolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer
Author(s) -
Makoto Ueno,
Soichiro Morinaga,
Yusuke Hashimoto,
Kumiko Umemoto,
Naoki Sasahira,
Akio Saiura,
Yousuke Seyama,
Goro Honda,
Tatsuya Ioka,
Hidenori Takahashi,
Atsushi Miyamoto,
Shoji Nakamori,
Michiaki Unno,
Tatsuyuki Takadate,
Nobumasa Mizuno,
Yasuhiro Shimizu,
Hideki Ueno,
Masanori Sugiyama,
Akira Fukutomi,
Satoshi Shimizu,
Takuji Okusaka,
Junji Furuse
Publication year - 2021
Publication title -
pancreas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.061
H-Index - 104
eISSN - 1536-4828
pISSN - 0885-3177
DOI - 10.1097/mpa.0000000000001702
Subject(s) - tolerability , medicine , gemcitabine , neutropenia , leukopenia , adverse effect , clinical endpoint , pancreatic cancer , gastroenterology , surgery , oncology , cancer , chemotherapy , clinical trial
The combination of gemcitabine plus nab-paclitaxel (GnP) has not been studied in Japanese patients with resectable pancreatic cancer (PC). This study aimed to assess the tolerability of adjuvant GnP in Japanese patients with resected PC.